Aryl sulfonic pyridoxine compounds with antiplatelet aggregation
characteristics for the treatment of cardiovascular and cardiovascular
related disease, are described. The methods are directed to administering
pharmaceutical compositions comprising aryl sulfonic pyridoxines.